A lack of clinicians frequently causes misdiagnosis of neuropathies and delay of treatment, especially in rural and underserved settings, claimed Dr Alberto De Lorenzo (University of Milan, Italy) [1]. As AI shows promise in aiding clinicians in both diagnosis and management decisions, Dr De Lorenzo and his group compared GPT-4oās performance with that of specialised and non-specialised neurologists in diagnosing real-life cases of polyneuropathy and in guiding confirmatory testing [1]. Standardised clinical summaries from 100 polyneuropathy cases were presented to GPT-4o in order to generate a leading diagnosis, two differential diagnoses, and a confirmatory test. The same 100 cases were reviewed by 36 neurologists from 10 countries, both specialists and non-specialists. They were allowed to revise their findings after reviewing GPT-4oās output.
Compared with specialised neurologists, GPT-4oās accuracy of the leading diagnosis was inferior (73.9% vs 65.5%; P=0.024). However, GPT-4o outperformed non-specialists (accuracy 65.5% vs 54.4%; P=0.007). When differential diagnoses were also considered, GPT-4o performed less well than specialists (88.1% vs 82.0%; P=0.042) but outperformed non-specialists (82.0% vs 68.5%; P<0.001). Dr De Lorenzo added that specialists only revised their diagnosis in 9% of cases after reviewing GPT-4o output, slightly and non-significantly increasing their performance from 73.9% to 75.0% (P=0.069); while non-specialised doctors revised their diagnosis in 21% of cases, significantly improving accuracy of their leading diagnosis and differential diagnosis from 54.4% to 57.0% (P=0.007). The most common GPT-4o errors were over-reliance on laboratory findings or patient history (38%), overlooking clinical information (16%), vague conclusions (16%), limited internal knowledge (9%), and reasonable but incorrect responses (22%).
āThis may be a first step towards managing and collecting evidence for the integration of these models in real-life clinical care,ā Dr De Lorenzo concluded, āespecially benefitting non-specialised clinicians when faced with a complex case of peripheral neuropathy.ā
- De Lorenzo A, et al. Chat-GPT-4o in diagnosis and management of real-life polyneuropathy cases: Comparative analysis with neurologists. OPR-023, EAN Congress 2025, 21-24 June 2025, Helsinki, Finland.
Medical writing support was provided by Michiel Tent.
Copyright ©2025 Medicom Medical Publishers
Posted on
Previous Article
« Lecanemab in AD: not a paradigm shift, but a small step forward Next Article
GLP-1R agonists reduce migraine burden in obese patients »
« Lecanemab in AD: not a paradigm shift, but a small step forward Next Article
GLP-1R agonists reduce migraine burden in obese patients »
Table of Contents: EAN 2025
Featured articles
Lecanemab in AD: not a paradigm shift, but a small step forward
Why a good result of migraine treatment may not be good enough
Online First
Similar efficacy of anti-CGRP mAbs in short- and long-term migraine prevention
Occipital nerve stimulation is no more effective than placebo in cluster headache
Rituximab does not halt progression in non-active secondary progressive MS
Encouraging results for adaptive DBS for Parkinsonās disease
CAR T cell therapy shows promise in severe autoimmune neuropathies
GLP-1R agonists reduce migraine burden in obese patients
Is ChatGPT helpful in diagnosing polyneuropathies?
Lecanemab in AD: not a paradigm shift, but a small step forward
Dementia doubles mortality risk 1 year after hip fracture
Real-world data confirms effectiveness and safety of ofatumumab in MS
Virus-specific T cells show promise in treating PML
Comparable effectiveness and persistence of ocrelizumab, natalizumab
Why a good result of migraine treatment may not be good enough
Long-term benefits of cipa/mig in late-onset Pompe disease
Earlier add-on treatment in myasthenia gravis improves outcomes
Related Articles
August 27, 2019
Antipsychotics increase mortality regardless of comorbidity
Ā© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com